Cancer drug developer NH Theraguix was incubated by Satt Pulsalys to advance a nanoparticle-based drug for solid tumours that works by enhancing the efficacy of radiotherapy treatment and MRI scans.

Novo and Sanofi Ventures returned to reinvest in Inozyme Pharma as it looks to advance its lead mineralisation disorder drug towards the clinic.

Varian Medical Systems co-led the series B round, which will fund the development of ABK Biomedical's embolic therapies.

Perspectives on sustainability and wellbeing are changing in response to health and environmental challenges, offering an opportunity to university-linked businesses.

Varian led a round for the targeted cancer drug developer that included existing investors such as Facit and Johnson & Johnson.

NUI Maynooth spinout Avectas has added capital to converted equity previously supplied by therapeutics developer Adapt Pharma among others.

UVA’s seed fund and corporate venturing unit PharmStandard Ventures featured in topical dry eye syndrome peptide spinout TearSolutions' financing round, taking its total to $21.5m.

SoftBank has tapped three executives to help run its $5bn Latin America-focused fund, with Paulo Passoni and Shu Nyatta to work alongside managing partner André Maciel.

The cosmetic surgery booking and reviews platform, which counts Tencent among its investors, has filed to go public in the US.

Lundbeckfonden Ventures-backed Trevi has filed for an $86.2m IPO to fund clinical trials for pruritus-focused drug treatments.